Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Ipamorelin vs GHRP-6

Both activate the GHS-R1a receptor, but their selectivity profiles diverge significantly. GHRP-6 produces robust GH release but also drives substantial increases in cortisol, prolactin, and appetite. The appetite stimulation from GHRP-6 is particularly pronoun

This comparison does not assign a generated winner or score.

  • Both activate the GHS-R1a receptor, but their selectivity profiles diverge significantly. GHRP-6 produces robust GH release but also drives substantial increases in cortisol, prolactin, and appetite. The appetite stimulation from GHRP-6 is particularly pronounced, a direct consequence of strong ghrelin receptor agonism in the hypothalamus. Ipamorelin achieves comparable GH output without these off-target effects, which is why it largely replaced GHRP-6 in modern stacking protocols.
More references

Related material

Comparison

Ipamorelin vs GHRP-2

GHRP-2 sits between Ipamorelin and GHRP-6 in the selectivity spectrum. It produces a slightly stronger GH pulse than Ipamorelin but also elevates cortisol and prolactin to a modes…

View details →
Comparison

CJC-1295 vs Sermorelin

Both are GHRH analogs targeting the same receptor, but they differ meaningfully in pharmacokinetics. Sermorelin is essentially the unmodified GHRH(1-29) fragment with a half-life …

View details →
Comparison

CJC-1295 vs Tesamorelin

Tesamorelin is the only GHRH analog with current FDA approval (granted in 2010 for HIV-associated lipodystrophy). It uses an N-terminal trans-3-hexenoic acid modification for DPP-…

View details →
Comparison

Quick Comparison

Type: CJC-1295 is a GHRH analog; Ipamorelin is a growth hormone secretagogue (GHRP). Mechanism: CJC-1295 activates GHRH receptors on pituitary somatotrophs; Ipamorelin activates g…

View details →